Literature DB >> 34251540

Dynapenia in digestive cancer outpatients: association with markers of functional and nutritional status (the FIGHTDIGO study).

Marine Perrier1,2, Marie-Amelie Ordan3,4, Coralie Barbe5, Camille Mazza3, Damien Botsen3, Johanna Moreau3,4, Yohann Renard6, Mathilde Brasseur3,4, Barbara Tailliere7, Philippe Regnault8, Eric Bertin9, Olivier Bouche3,4.   

Abstract

BACKGROUND: The FIGHTDIGO study determined the feasibility and acceptability of handgrip strength (HGS) measurement in digestive cancer outpatients.
PURPOSE: To assess the relationship between muscle strength and markers of functional and nutritional status in this population.
DESIGN: In this prospective study, a total of 201 patients were followed during 6 months and were asked to perform HGS measurement at each hospitalization. Anthropometric measurements, laboratory tests, and performance status (PS) evaluation were collected. The modified Glasgow Prognostic Score (mGPS) was calculated using CRP and albumin levels. Severe malnutrition was defined as body mass index (BMI) < 18 kg/m2 in patients > 70 years old, and BMI < 16 kg/m2 in those < 70 years old. Dynapenia was defined as HGS < 30 kg (men) and < 20 kg (women). Mixed logistic regressions and mixed linear regressions were performed to study factors associated with dynapenia and HGS value, respectively.
RESULTS: A total of 879 HGS measurements were analyzed. Dynapenia occurred in 177 measurements (20.1%). BMI and HGS were significantly associated in univariate analysis (p = 0.001). In multivariate analysis, mGPS score (β =  - 0.54 ± 0.31; p = 0.06) and severe malnutrition (β =  - 2.8 ± 1.4; p = 0.08) tended to be associated with HGS. Dynapenia was only associated with functional status impairment in univariate analysis (n = 140/803, 17.4% in ECOG 0 and 1 versus n = 37/76, 58.7% in ECOG 2 and 3; p = 0.002).
CONCLUSIONS: Identification of dynapenia using HGS measurement may be useful to predict nutritional vulnerability in digestive cancer outpatients undergoing chemotherapy. Patients could then benefit from nutritional support, adapted physical activity programs, and early therapeutic adjustments. Trial registration ClinicalTrials.gov, NCT02797197.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Digestive system neoplasms; Dynapenia; Malnutrition; Muscle strength; Sarcopenia

Mesh:

Year:  2021        PMID: 34251540     DOI: 10.1007/s00520-021-06416-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  25 in total

Review 1.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.

Authors:  Donald C McMillan
Journal:  Cancer Treat Rev       Date:  2012-09-17       Impact factor: 12.111

2.  Relationship between nutritional status and the Glasgow Prognostic Score in patients with colorectal cancer.

Authors:  Sílvia Fernandes Maurício; Jacqueline Braga da Silva; Tatiana Bering; Maria Isabel Toulson Davisson Correia
Journal:  Nutrition       Date:  2013-01-05       Impact factor: 4.008

3.  Association between an inflammatory-nutritional index and nutritional status in cancer patients.

Authors:  Carla Alberici Pastore; Silvana Paiva Orlandi; María Cristina González
Journal:  Nutr Hosp       Date:  2013 Jan-Feb       Impact factor: 1.057

4.  Adverse Effects of Preoperative Sarcopenia on Postoperative Complications of Patients With Gastric Cancer.

Authors:  Tatsuro Tamura; Katsunobu Sakurai; Mikio Nambara; Yuichiro Miki; Takahiro Toyokawa; Naoshi Kubo; Hiroaki Tanaka; Kazuya Muguruma; Masakazu Yashiro; Masaichi Ohira
Journal:  Anticancer Res       Date:  2019-02       Impact factor: 2.480

5.  Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer.

Authors:  Kotaro Hirashima; Masayuki Watanabe; Hironobu Shigaki; Yu Imamura; Satoshi Ida; Masaaki Iwatsuki; Takatsugu Ishimoto; Shiro Iwagami; Yoshifumi Baba; Hideo Baba
Journal:  J Gastroenterol       Date:  2013-07-03       Impact factor: 7.527

6.  Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer.

Authors:  Maximilien Barret; Sami Antoun; Cécile Dalban; David Malka; Touraj Mansourbakht; Aziz Zaanan; Ewa Latko; Julien Taieb
Journal:  Nutr Cancer       Date:  2014-04-07       Impact factor: 2.900

7.  Nutritional screening and early treatment of malnutrition in cancer patients.

Authors:  Lidia Santarpia; Franco Contaldo; Fabrizio Pasanisi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-02-22       Impact factor: 12.910

8.  Sarcopenia: revised European consensus on definition and diagnosis.

Authors:  Alfonso J Cruz-Jentoft; Gülistan Bahat; Jürgen Bauer; Yves Boirie; Olivier Bruyère; Tommy Cederholm; Cyrus Cooper; Francesco Landi; Yves Rolland; Avan Aihie Sayer; Stéphane M Schneider; Cornel C Sieber; Eva Topinkova; Maurits Vandewoude; Marjolein Visser; Mauro Zamboni
Journal:  Age Ageing       Date:  2019-01-01       Impact factor: 10.668

9.  Prognostic value of the Glasgow prognostic score in colorectal cancer: a meta-analysis of 9,839 patients.

Authors:  Xin Lu; Wanying Guo; Wei Xu; Xuelei Zhang; Zhijie Shi; Leizhen Zheng; Wenzhao Zhao
Journal:  Cancer Manag Res       Date:  2018-12-24       Impact factor: 3.989

10.  Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer.

Authors:  L M Forrest; D C McMillan; C S McArdle; W J Angerson; D J Dunlop
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

View more
  1 in total

1.  Feasibility and Impact of Adapted Physical Activity (APA) in Cancer Outpatients Beginning Medical Anti-Tumoral Treatment: The UMA-CHAPA Study.

Authors:  Amélie Lemoine; Marine Perrier; Camille Mazza; Anne Quinquenel; Mathilde Brasseur; Alain Delmer; Hervé Vallerand; Maxime Dewolf; Eric Bertin; Coralie Barbe; Damien Botsen; Olivier Bouché
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.